• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项多机构研究,旨在评估免疫组织化学自动全片评分在非小细胞肺癌中评估程序性死亡配体1(PD-L1)表达的应用。

A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.

作者信息

Taylor Clive R, Jadhav Anagha P, Gholap Abhi, Kamble Gurunath, Huang Jiaoti, Gown Allen, Doshi Isha, Rimm David L

机构信息

Department of Pathology, University of Southern California, Los Angeles.

OptraSCAN, Pune, India.

出版信息

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.

DOI:10.1097/PAI.0000000000000737
PMID:30640753
Abstract

Assessment of programmed death-ligand 1 (PD-L1) expression is a critical part of patient management for immunotherapy. However, studies have shown that pathologist-based analysis lacks reproducibility, especially for immune cell expression. The purpose of this study was to validate reproducibility of the automated machine-based Optra image analysis for PD-L1 immunohistochemistry for both tumor cells (TCs) and immune cells. We compared conventional pathologists' scores for both tumor and immune cell positivity separately using 22c3 antibody on the Dako Link 48 platform for PD-L1 expression in non-small cell lung carcinoma. We assessed interpretation first by pathologists and second by PD-L1 image analysis scores. Lin's concordance correlation coefficients (LCCs) for each pathologist were measured to assess variability between pathologists and between pathologists and Optra automated quantitative scores in scoring both tumor and immune cells. Lin's LCCs to evaluate the correlation between pathologists for TC was 0.75 [95% confidence interval (CI), 0.64-0.81] and 0.40 (95% CI, 0.40-0.62) for immune cell scoring. Pathologists were highly concordant for tumor scoring, but not for immune cell scoring, which is similar to previously reported studies where agreement is higher in TCs than immune cells. The LCCs between conventional pathologists' read and the machine score were 0.80 (95% CI, 0.74-0.85) for TCs and 0.70 (95% CI, 0.60-0.76) for immune cell population. This is considered excellent agreement for TCs and good concordance for immune cells. The automated scoring methods showed concordance with the pathologists' average scores that were comparable to interpathologist scores. This suggests promise for Optra automated assessment of PD-L1 in non-small cell lung cancer.

摘要

程序性死亡配体1(PD-L1)表达评估是免疫治疗患者管理的关键部分。然而,研究表明,基于病理学家的分析缺乏可重复性,尤其是对于免疫细胞表达。本研究的目的是验证基于自动化机器的Optra图像分析在非小细胞肺癌中对肿瘤细胞(TCs)和免疫细胞进行PD-L1免疫组化分析的可重复性。我们在Dako Link 48平台上使用22c3抗体,分别比较了传统病理学家对肿瘤和免疫细胞阳性的评分,以评估非小细胞肺癌中PD-L1的表达。我们首先由病理学家进行解读,其次通过PD-L1图像分析评分进行评估。测量每位病理学家的林氏一致性相关系数(LCCs),以评估病理学家之间以及病理学家与Optra自动定量评分在对肿瘤和免疫细胞评分时的变异性。评估病理学家之间TC相关性的林氏LCCs为0.75[95%置信区间(CI),0.64 - 0.81],免疫细胞评分的林氏LCCs为0.40(95%CI,0.40 - 0.62)。病理学家在肿瘤评分方面高度一致,但在免疫细胞评分方面不一致,这与先前报道的研究相似,即TCs中的一致性高于免疫细胞。传统病理学家的读数与机器评分之间的LCCs,TCs为0.80(95%CI,0.74 - 0.85),免疫细胞群体为0.70(95%CI,0.60 - 0.76)。这被认为是TCs的极佳一致性和免疫细胞的良好一致性。自动评分方法与病理学家的平均评分显示出一致性,与病理学家之间的评分相当。这表明Optra在非小细胞肺癌中对PD-L1进行自动评估具有前景。

相似文献

1
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.一项多机构研究,旨在评估免疫组织化学自动全片评分在非小细胞肺癌中评估程序性死亡配体1(PD-L1)表达的应用。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.
2
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.一项非小细胞肺癌中 PD-L1 表达的前瞻性、多机构、基于病理学家的 4 种免疫组化检测评估。
JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.
3
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.使用自动化图像分析比较非小细胞肺癌中不同诊断 PD-L1 检测方法的连续测量值。
Mod Pathol. 2020 Mar;33(3):380-390. doi: 10.1038/s41379-019-0349-y. Epub 2019 Sep 16.
4
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.非小细胞肺癌中程序性死亡配体1(PD-L1)表达异质性的定量分析与病理学家解读比较
Mod Pathol. 2017 Mar;30(3):340-349. doi: 10.1038/modpathol.2016.186. Epub 2016 Nov 11.
5
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.基于多阶段集成策略的非小细胞肺癌 PD-L1 表达自动肿瘤比例评分。
J Transl Med. 2021 Jun 7;19(1):249. doi: 10.1186/s12967-021-02898-z.
6
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.肺鳞状细胞癌中 PD-L1(22C3)表达的自动肿瘤比例评分分析。
Sci Rep. 2021 Aug 5;11(1):15907. doi: 10.1038/s41598-021-95372-1.
7
Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.评估用于肺癌程序性死亡配体-1(PD-L1)诊断检测评分的在线培训工具。
Diagn Pathol. 2020 Apr 17;15(1):37. doi: 10.1186/s13000-020-00953-9.
8
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.肿瘤浸润淋巴细胞中程序性死亡受体 1 表达与非小细胞肺癌中程序性死亡配体 1 表达的相关性。
Arch Pathol Lab Med. 2018 Nov;142(11):1388-1393. doi: 10.5858/arpa.2017-0516-OA. Epub 2018 Feb 12.
9
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.利用数字图像分析检测胃癌中的 PD-L1 表达:陷阱及与病理学家解读的相关性。
Virchows Arch. 2020 Feb;476(2):243-250. doi: 10.1007/s00428-019-02653-2. Epub 2019 Aug 28.
10
A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?基于深度学习的非小细胞肺癌程序性死亡配体 1 免疫组织化学评分检测法:它能帮助病理学家评分吗?
Mod Pathol. 2024 Jun;37(6):100485. doi: 10.1016/j.modpat.2024.100485. Epub 2024 Apr 6.

引用本文的文献

1
Artificial Intelligence (AI) for Programmed Death Ligand-1 (PD-L1) Immunohistochemical Assessment in Urothelial Carcinomas: "Teaching" Cell Differentiation to AI Systems.人工智能用于尿路上皮癌程序性死亡配体-1(PD-L1)免疫组化评估:向人工智能系统“传授”细胞分化
Life (Basel). 2025 May 22;15(6):839. doi: 10.3390/life15060839.
2
Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma.基于人工智能的弥漫性大B细胞淋巴瘤中PD-L1表达评估
NPJ Precis Oncol. 2024 Mar 27;8(1):76. doi: 10.1038/s41698-024-00577-y.
3
Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
比较深度学习和病理学家对非小细胞肺癌全切片图像中细胞水平 PD-L1 表达的定量分析。
Sci Rep. 2024 Mar 26;14(1):7136. doi: 10.1038/s41598-024-57067-1.
4
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.三阴性乳腺癌中的免疫生物标志物:提高当前检测方法的预测性
J Pers Med. 2023 Jul 23;13(7):1176. doi: 10.3390/jpm13071176.
5
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.人工智能驱动和手动定量检测程序性死亡配体 1(PD-L1)表达与纳武利尤单抗±伊匹单抗治疗患者结局的关联。
Mod Pathol. 2022 Nov;35(11):1529-1539. doi: 10.1038/s41379-022-01119-2. Epub 2022 Jul 15.
6
Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry.用于PD-L1免疫组织化学评分的计算机图像分析算法的开发与应用
Immunooncol Technol. 2020 May 11;6:2-8. doi: 10.1016/j.iotech.2020.04.001. eCollection 2020 Jun.
7
Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.开发和验证一种基于监督深度学习的算法,用于非小细胞肺癌中程序性死亡配体 1 肿瘤比例评分的全自动全切片评估。
Histopathology. 2022 Mar;80(4):635-647. doi: 10.1111/his.14571. Epub 2021 Nov 16.
8
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.在头颈部鳞状细胞癌中使用人工智能进行程序性死亡受体1配体(PD-L1)自动评分
Cancers (Basel). 2021 Aug 31;13(17):4409. doi: 10.3390/cancers13174409.
9
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.使用开源软件对非小细胞肺癌进行自动化程序性死亡配体1(PD-L1)评分
Pathol Oncol Res. 2021 Mar 26;27:609717. doi: 10.3389/pore.2021.609717. eCollection 2021.
10
Digital Slide Assessment for Programmed Death-Ligand 1 Combined Positive Score in Head and Neck Squamous Carcinoma: Focus on Validation and Vision.头颈部鳞状细胞癌程序性死亡配体1联合阳性评分的数字切片评估:聚焦验证与展望
Front Artif Intell. 2021 Jun 4;4:684034. doi: 10.3389/frai.2021.684034. eCollection 2021.